Turning Point in COVID-19 Severity and Fatality During the Pandemic: a National Cohort Study in Qatar

Objective: To assess the evolution of COVID-19 severity and fatality in a unique setting that consistently applied, throughout the pandemic, rigorous and standardised criteria for defining severe COVID-19 outcomes.

Methods And Analysis: We conducted a national cohort study on 312 109 Qatari citizens to investigate incidence of severe, critical or fatal COVID-19 classified according to the WHO criteria between 28 February 2020 and 21 April 2023. Incidence rates for severe, critical or fatal COVID-19 were estimated during the pre-omicron phase, first omicron wave, combined phases and throughout the pandemic.

Results: Cumulative incidence of severe, critical or fatal COVID-19 after 3.14 years of follow-up was 0.45% (95% CI 0.43% to 0.47%). Incidence rate for severe, critical or fatal COVID-19 throughout the pandemic was 1.43 (95% CI 1.35 to 1.50) per 1000 person years. In the pre-omicron phase, first omicron wave, and combined phases, it was 2.01 (95% CI 1.90 to 2.13), 3.70 (95% CI 3.25 to 4.22) and 2.18 (95% CI 2.07 to 2.30) per 1000 person years, respectively. The post-first omicron phase saw a drastic drop to 0.10 (95% CI 0.08 to 0.14) per 1000 person years, a 95.4% reduction. Among all severe, critical and fatal cases, 99.5% occurred during the primary infection. Cumulative incidence of fatal COVID-19 was 0.042% (95% CI 0.036% to 0.050%), with an incidence rate of 0.13 (95% CI 0.11 to 0.16) per 1000 person years. In the post-first omicron phase, incidence rate of fatal COVID-19 decreased by 90.0% compared with earlier stages. Both severity and fatality exhibited an exponential increase with age and a linear increase with the number of coexisting conditions.

Conclusion: The conclusion of the first omicron wave was a turning point in the severity of the pandemic. While vaccination and enhanced case management reduced severity gradually, the rapid accumulation of natural immunity during the first omicron wave appears to have played a critical role in driving this shift in severity.

References

Chemaitelly H, Tang P, Hasan M, Almukdad S, Yassine H, Benslimane F . Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar. N Engl J Med. 2021; 385(24):e83. PMC: 8522799. DOI: 10.1056/NEJMoa2114114. View

Altarawneh H, Chemaitelly H, Ayoub H, Hasan M, Coyle P, Yassine H . Protective Effect of Previous SARS-CoV-2 Infection against Omicron BA.4 and BA.5 Subvariants. N Engl J Med. 2022; 387(17):1620-1622. PMC: 9559315. DOI: 10.1056/NEJMc2209306. View

Butt A, Dargham S, Tang P, Chemaitelly H, Hasan M, Coyle P . COVID-19 disease severity in persons infected with the Omicron variant compared with the Delta variant in Qatar. J Glob Health. 2022; 12:05032. PMC: 9253930. DOI: 10.7189/jogh.12.05032. View

Chemaitelly H, Ayoub H, Almukdad S, Faust J, Tang P, Coyle P . Bivalent mRNA-1273.214 vaccine effectiveness against SARS-CoV-2 omicron XBB* infections. J Travel Med. 2023; 30(5). PMC: 10481416. DOI: 10.1093/jtm/taad106. View

Butt A, Dargham S, Coyle P, Yassine H, Al-Khal A, Abou-Samra A . COVID-19 Disease Severity in Persons Infected With Omicron BA.1 and BA.2 Sublineages and Association With Vaccination Status. JAMA Intern Med. 2022; 182(10):1097-1099. PMC: 9396464. DOI: 10.1001/jamainternmed.2022.3351. View

Abu-Raddad L, Chemaitelly H, Bertollini R . Effectiveness of mRNA-1273 and BNT162b2 Vaccines in Qatar. N Engl J Med. 2022; 386(8):799-800. PMC: 8796790. DOI: 10.1056/NEJMc2117933. View

Feikin D, Abu-Raddad L, Andrews N, Davies M, Higdon M, Orenstein W . Assessing vaccine effectiveness against severe COVID-19 disease caused by omicron variant. Report from a meeting of the World Health Organization. Vaccine. 2022; 40(26):3516-3527. PMC: 9058052. DOI: 10.1016/j.vaccine.2022.04.069. View

. Estimating excess mortality due to the COVID-19 pandemic: a systematic analysis of COVID-19-related mortality, 2020-21. Lancet. 2022; 399(10334):1513-1536. PMC: 8912932. DOI: 10.1016/S0140-6736(21)02796-3. View

Tang P, Hasan M, Chemaitelly H, Yassine H, Benslimane F, Al Khatib H . BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar. Nat Med. 2021; 27(12):2136-2143. DOI: 10.1038/s41591-021-01583-4. View

10.

Qassim S, Chemaitelly H, Ayoub H, Coyle P, Tang P, Yassine H . Population immunity of natural infection, primary-series vaccination, and booster vaccination in Qatar during the COVID-19 pandemic: an observational study. EClinicalMedicine. 2023; 62:102102. PMC: 10393554. DOI: 10.1016/j.eclinm.2023.102102. View

11.

Chemaitelly H, Faust J, Krumholz H, Ayoub H, Tang P, Coyle P . Short- and longer-term all-cause mortality among SARS-CoV-2- infected individuals and the pull-forward phenomenon in Qatar: a national cohort study. Int J Infect Dis. 2023; 136:81-90. DOI: 10.1016/j.ijid.2023.09.005. View

12.

Faust J, Renton B, Chen A, Du C, Liang C, Li S . Uncoupling of all-cause excess mortality from COVID-19 cases in a highly vaccinated state. Lancet Infect Dis. 2022; 22(10):1419-1420. PMC: 9395168. DOI: 10.1016/S1473-3099(22)00547-3. View

13.

Altarawneh H, Chemaitelly H, Hasan M, Ayoub H, Qassim S, Almukdad S . Protection against the Omicron Variant from Previous SARS-CoV-2 Infection. N Engl J Med. 2022; 386(13):1288-1290. PMC: 8849180. DOI: 10.1056/NEJMc2200133. View

14.

Pilz S, Theiler-Schwetz V, Trummer C, Krause R, Ioannidis J . SARS-CoV-2 reinfections: Overview of efficacy and duration of natural and hybrid immunity. Environ Res. 2022; 209:112911. PMC: 8824301. DOI: 10.1016/j.envres.2022.112911. View

15.

Msemburi W, Karlinsky A, Knutson V, Aleshin-Guendel S, Chatterji S, Wakefield J . The WHO estimates of excess mortality associated with the COVID-19 pandemic. Nature. 2022; 613(7942):130-137. DOI: 10.1038/s41586-022-05522-2. View

16.

Ayoub H, Mumtaz G, Seedat S, Makhoul M, Chemaitelly H, Abu-Raddad L . Estimates of global SARS-CoV-2 infection exposure, infection morbidity, and infection mortality rates in 2020. Glob Epidemiol. 2021; 3:100068. PMC: 8609676. DOI: 10.1016/j.gloepi.2021.100068. View

17.

Zaqout A, Almaslamani M, Chemaitelly H, Hashim S, Ittaman A, Alimam A . Effectiveness of the neutralizing antibody sotrovimab among high-risk patients with mild-to-moderate SARS-CoV-2 in Qatar. Int J Infect Dis. 2022; 124:96-103. PMC: 9484101. DOI: 10.1016/j.ijid.2022.09.023. View

18.

Seedat S, Chemaitelly H, Ayoub H, Makhoul M, Mumtaz G, Al Kanaani Z . SARS-CoV-2 infection hospitalization, severity, criticality, and fatality rates in Qatar. Sci Rep. 2021; 11(1):18182. PMC: 8440606. DOI: 10.1038/s41598-021-97606-8. View

19.

Altarawneh H, Chemaitelly H, Ayoub H, Tang P, Hasan M, Yassine H . Effects of previous infection, vaccination, and hybrid immunity against symptomatic Alpha, Beta, and Delta SARS-CoV-2 infections: an observational study. EBioMedicine. 2023; 95:104734. PMC: 10404859. DOI: 10.1016/j.ebiom.2023.104734. View

20.

Al-Thani M, Farag E, Bertollini R, Al Romaihi H, Abdeen S, Abdelkarim A . SARS-CoV-2 Infection Is at Herd Immunity in the Majority Segment of the Population of Qatar. Open Forum Infect Dis. 2021; 8(8):ofab221. PMC: 8135898. DOI: 10.1093/ofid/ofab221. View